Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,875 GBX | -2.19% |
|
-6.25% | +4.81% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.81% | 5.26B | |
+55.95% | 819B | |
+43.62% | 638B | |
-6.98% | 351B | |
+19.08% | 329B | |
+9.05% | 298B | |
+16.30% | 242B | |
+2.41% | 225B | |
+12.47% | 217B | |
+8.91% | 168B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, H1 2023 Pre Recorded Earnings Call, Aug 03, 2023